Infinity Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-06-16: Reporting owner EVNIN ANTHONY B; Form 4; Security Stock Option(right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-16: Reporting owner BEIER DAVID W; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-16: Reporting owner GAYNOR RICHARD; Form 4; Security Stock Option(right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-16: Reporting owner Agresta Samuel; Form 4; Security Stock Option(right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-06-16 | EVNIN ANTHONY B Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | BEIER DAVID W Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | GAYNOR RICHARD Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | Agresta Samuel Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | SELBY NORMAN C Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | SELBY NORMAN C Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-06-16 | SCHWARTZ BRIAN Director | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $0.68 exercise price | 2022-06-16 | |
| 2022-03-30 | KANGO SUJAY Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $1.13 exercise price | 2022-03-31 | |
| 2022-01-11 | Perkins Adelene Q Director, Officer (Chief Executive Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +576,100 576,100 owned after | $1.53 exercise price | 2022-01-12 | |
| 2022-01-11 | BLOCH LAWRENCE E Officer (President) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +335,000 335,000 owned after | $1.53 exercise price | 2022-01-12 | |
| 2022-01-11 | Tasker Seth A Officer (Chief Business Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $1.53 exercise price | 2022-01-12 | |
| 2022-01-11 | Peluso Stephane Officer (Chief Scientific Officer) | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,027 87,027 owned after | $1.53 exercise price | 2022-01-12 | |
| 2022-01-11 | Ilaria Robert Jr. Officer (Chief Medical Officer) | 4 | Stock Option(right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +87,472 87,472 owned after | $1.53 exercise price | 2022-01-12 |